拜瑪林製藥 BMRN 深 滬
已收盤 12-19 16:00:00 美东时间
61.15
+9.200
+17.71%
華盛通- 最 高63.89
- 今 開54.80
- 成交量 1852.01万股
- 最 低 54.39
- 昨 收 51.95
- 總市值 117.41亿
- 52周最高 73.51
- 市盈率 靜 27.70
- 換手率 9.65%
- 52周最低 50.76
- 委 比 -87.70%
- 總股本 1.92亿
- 歷史最高 151.75
- 量 比 9.16
- 振 幅 18.29%
- 歷史最低 23.735
- 每 手 1
- 風險率 5.68%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股周涨跌榜 | 特朗普媒体科技集团周涨51.1%，拟并购TAE转型聚变能源公司；Medline周涨43.6%
DJT周涨51.1%，拟并购TAE转型聚变能源公司；Medline周涨43.6%，本周首挂上市，为年内全球最大规模IPO；爱美医疗周涨34.4%，获拜玛林制药48亿美元收购>>
12-20 09:40
Tech Stocks Rally, Silver Hits New Record Highs: What's Moving Markets Friday?
U.S. stocks pushed higher on Friday as investors continued to show optimism towards the AI theme and positioned into December's "triple witching" session.
12-20 02:10
BioMarin Boosts Rare Disease Portfolio With Amicus Buyout, Stocks Rally
BioMarin acquires Amicus for $4.8B, expanding its rare disease portfolio with Fabry and Pompe therapies, in a deal expected to close Q2 2026.
12-20 00:07
GSK Deal Is Key Validation For CAMP4's Drug Discovery Platform: Analyst
CAMP4 signs ASO collaboration with GSK, securing $17.5 million upfront as analysts reaffirm Outperform and highlight 2026 clinical milestones.
12-19 23:36
BioMarin To Acquire Amicus For $14.50/Shr In All-Cash Transaction For Total Equity Value Of ~$4.8B
BioMarin to Gain Galafold® (migalastat) for Fabry Disease and Pombiliti® (cipaglucosidase alfa-atga) + Opfolda® (miglustat) for Pompe Disease, Adding Two Marketed, High-Growth Products with $599 Million in
12-19 20:48
'Secretary Kennedy Adds Duchenne Muscular Dystrophy, Metachromatic Leukodystrophy To Newborn Screenings' - HHS
https://www.hhs.gov/press-room/secretary-kennedy-adds-duchenne-muscular-dystrophy-metachromatic-leukodystrophy-to-newborn-screenings.html#:~:text=WASHINGTON%E2%80%94DECEMBER%2016%2C%202025%20%E2%80%94,scientific%20review
12-17 00:34
美股大行评级 | 美鹰服饰、CrowdStrike、迈威尔科技获多家机构上调目标价；ACHC、GitLab、Okta遭多家机构下调目标价
今日重点评级关注：Guggenheim：维持Cybin Inc. Common Shares"买入"评级，目标价从39美元升至48美元；HC Wainwright & Co.：维持Capricor Therapeutics"买入"评级，目标价从24美元升至60美元
12-04 09:38
Leerink Partners Downgrades BioMarin Pharmaceutical to Market Perform, Lowers Price Target to $60
Leerink Partners analyst Joseph Schwartz downgrades BioMarin Pharmaceutical (NASDAQ:BMRN) from Outperform to Market Perform and lowers the price target from $82 to $60.
12-03 21:35
Goldman says healthcare is ripe for stock picking; here's some they like
The healthcare sector’s slump had created opportunities for stock-pickers rather than broad sector gains, Goldman Sachs strategist David Kostin said. Healthcare (XLV) has lagged the S&P 500 (SPY) (IVV...
11-11 00:19
美股大行评级 | 绩后评级扎堆！高通、ARM、礼来、Snap、Robinhood等获多家大行上调目标价；DoorDash、多邻国、Figma、飞塔信息、HubSpot等遭下调目标价
高通、ARM、礼来、Snap、Robinhood等获多家大行上调目标价；Adient、DoorDash、多邻国、Figma、飞塔信息、HubSpot、康丽数码等遭大行下调目标价
11-07 10:14
